相似图钉
FDA Authorizes Abbott's Libre Duo Glucose-Ketone Sensor
已确认可信度 87%29天前The release is datelined "ABBOTT PARK, Ill., Aug. 25, 2026" and says Abbott "today announced U.S. Food and Drug Administration (FDA[2][3]) authorization of its Libre Duo 10 Day system"; the FDA's De Novo record gives the same decision date, 08/25/2026.The FDA authorized Abbott's Libre Duo 10 Day, the first wearable to continuously track both glucose and ketones, which alerts people with diabetes aged 2 and older to rising ketones before diabetic ketoacidosis.0.61- 0.61
NVIDIA Vera Rubin NVL72 Debuts in MLPerf Inference v6.1
已确认可信度 86%7天前MLCommons[4] published the MLPerf Inference v6.1 results on 16 September 2026 - its GlobeNewswire release is datelined 'SAN FRANCISCO, Sept. 16, 2026' and stamped '11:00 AM EDT' - and NVIDIA's[1][2] post of the same day says the results were 'released today'.In its first peer-reviewed benchmark, NVIDIA's Vera Rubin NVL72 rack posted up to 3.7x the throughput of GB300 NVL72 on Qwen3-VL and 2.5x on DeepSeek-R1, submitted in the preview category of MLCommons' MLPerf Inference v6.1 round.0.60Asus ZenScreen MB16AC 15.6-in USB monitor launching soon
已确认可信度 83%9.4年前Happened as dated, per hexus.net[1]: "…r release after a rather long wait - it was unveiled at IFA 2016 last August. This 15.6-inch screen…"It's a 15.6-inch full HD (1920 x 1080 pixels) IPS panel based device. Asus Zen devices are often pretty thin and this is no exception at 8mm. Improving its portability credentials is its weight of just 780g. Asus includes an ultra-thin 1mm foldable smart case with the screen, which provides screen protection and a further horizontal or vertical stand option.$299.000.60- 0.59
BGF MDI 320/14.4/9.6 μG's Phase 3 Trial in COPD Reads Out
预估可信度 50%1.2年后ClinicalTrials.gov[1] lists 2027-12-03 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of BGF MDI 320/14.4/9.6 μG in copd reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 5,000 participants. This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.0.59- 0.59
Intel Preparing to Launch New Xeon Processors for Potential Mac Pro Upgrade
已确认可信度 89%12年前Happened as dated, per macrumors.com[1]: "Intel Preparing to Launch New Xeon Processors for Potential Mac Pro Upgrade Aft…"Potential Mac Pro customers may now, be starting to look forward to the first update for the redesigned Mac Pro, as Intel appears set to launch new processors appropriate for the Mac Pro next month. Intel's "Grantley" Xeon E5 v3 chips are nearly ready to ship as successors to the current "Romley" Xeon E5 v2 chips used in the Mac Pro.0.59Audio-Technica ATH-AL5NC
已确认可信度 86%14天前Engadget's[4] launch report of September 9, 2026 (https://www.engadget.com/2253160/audio-technicas-new-wireless-ath-al5nc-completes-its-open-back-headphone-lineup/) states the ATH-AL5NC 'are available today for $279', so September 9, 2026 is the day they went on sale.Wireless open-back headphones with 53mm drivers and LDAC hi-res audio support.$279.000.59J&J Proposes $5.5 Billion Deal to Settle 76,000 Ovarian Cancer Talc Claims
已确认可信度 82%58天前J&J's release is datelined "New Brunswick, N.J. - JULY 27, 2026 - Johnson & Johnson (NYSE: JNJ[1]) ... today announced", and the copy filed as Exhibit 99.1 to its 8-K is marked "FOR RELEASE AT 6:15PM ET", 22:15 UTC in EDT.Johnson & Johnson announced a proposed resolution of its remaining ovarian talc litigation, about 76,000 claims, with a $5.5 billion commitment paid per claim - no more than $3 billion in 2027 and nothing more before 2028 - if at least 95% of claimants take part.$5.5B0.59Elecoglipron's Phase 3 Trial in Type 2 Diabetes Mellitus Reads Out
预估可信度 50%1.8年后ClinicalTrials.gov[1] lists 2028-07-05 as the estimated primary completion date; a sponsor's estimate, and trials of this size routinely slip.AstraZeneca's phase 3 trial of Elecoglipron in type 2 diabetes mellitus reaches primary completion, the point at which the last participant's primary outcome is measured. The trial enrolled 2,000 participants. The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.0.59Rotel Michi Prestige P430
预估可信度 69%7天后Availability is given only as a month: Rotel's[1] Michi Prestige launch coverage (https://www.whathifi[3].com/hi-fi/stereo-amplifiers/double-drop-rotel-expands-its-premium-michi-portfolio-with-a-new-stereo-amplifier-and-preamplifier, announced 1 September 2026) puts the P430 on sale 'from September 2026' with no specific day. Dated to the last day of that month, 30 September 2026, as an estimate.High-end stereo preamplifier with an ESS Sabre DAC, Roon support, and DSD256.$4K0.59
